

# Aspetti dietetici nelle dislipoproteinemie

## Bibliografia

- [1] Marcovina SM, Morrisett JD. Structure and metabolism of Lp(a). *Curr Opin Lipidol* 1995, 6: 136-145.
- [2] Rosenson RS, Brewer HB, Chapman MJ, Fazio S, Hussain MM, Kontush A et al. HDL measure, particle heterogeneity, proposed nomenclature and relation to atherosclerotic cardiovascular events. *Clin Chem* 2011, 57: 392-410.
- [3] Frank PG, Marcel YL. Apo-AI: structure-function relationship. *J Lipid Res* 2000, 103: 2126-2131.
- [4] Thomas MJ, Bhat S, Sorci-Thomas MG. Three dimensional models of HDL apo-AI: implications for its assembly and function. *J Lipid Res* 2008, 49: 1875-1883.
- [5] Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apo-B lipoprotein assembly. *J Lipid Res* 2003, 44: 22-32.
- [6] Brodsky JL, Fisher EA. The many interesting pathways underlying apo-B secretion and degradation. *Trends Endocrinol Metab* 2008, 19: 254-259.
- [7] De Barros JP, Boualam A, Gautier T, Dumont L, Verges B, Masson D et al. Apolipoprotein CI is a physiological regulator of CETP activity in human plasma but not in rabbit. *J Lipid Res* 2009, 50: 1842-1851.
- [8] Yao Z, Wang Y. Apo-CIII and hepatic triglyceride-rich lipoprotein production. *Curr Opin Lipidol* 2012, 23: 206-212.
- [9] Mensenkamp AR, Jong MC, van Goor H, van Luyn MJ, Bloks V, Havinga R et al. Apo-E participates in the regulation of VLDL-triglyceride secretion by the liver. *J Biol Chem* 1999, 274: 35711-35718.
- [10] Iqbal J, Hussain MM. Intestinal lipid absorption. *Am J Physiol Endo Metab* 2009, 296: E1183-1194.
- [11] Neeli I, Siddiqi SA, Siddiqi S, Mahani J, Lagakos WS, Binas B, et al. Liver fatty acid binding protein initiates budding of pre-chylomicron transport vesicles from intestinal endoplasmic reticulum. *J Biol Chem* 2007, 282: 17974-17984.
- [12] Mortimer BC, Beveridge DJ, Martins IJ, Redgrave TG. Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor deficient mice and apo-E deficient mice. *J Biol Chem* 1995, 270: 28767-28776.
- [13] MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witzum JL, et al. Liver heparin sulphate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptors family members. *J Clin Invest* 2007, 117: 153-164.
- [14] Dallinga-Thie GM, Franssen R, Mooij HL, Visser ME, Hassing HC, Peelman F, et al. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. *Atherosclerosis* 2010, 211: 1-8.
- [15] Lund-Katz S, Phillips MC. HDL structure-function and the role in reverse cholesterol transport. *Subcell Biochem* 2010, 51: 183-227.
- [16] Bruham LR, Kruij JK, Iqbal J, Fievet C, Timmins JM, Pape TD, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. *J Clin Invest* 2006, 116: 1052-1062.
- [17] Thuahnai ST, Lund-Katz S, Williams DL, Phillips MC. Scavenger receptor class B, type I-mediated uptake of various lipids into cells. *J Biol Chem* 2001, 276: 43801-43808.
- [18] Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis. *J Clin Invest* 2002, 109: 1125-1131.
- [19] Zheng C, Murdoch SJ, Brunzell JD, Sacks FM. Lipoproteins lipase bound to apo-B lipoproteins accelerates clearance of postprandial lipoproteins in humans. *Arterioscler Thromb Vasc Biol* 2006, 26: 891-896.
- [20] Connelly PW. The role of HL in lipoprotein metabolism. *Clin Chim Acta* 1999, 286: 243-255.
- [21] Francone OL, Gurakar A, Fielding C. Distributions and functions of LCAT and CETP in plasma lipoproteins. *J Biol Chem* 1989, 264: 7066-7072.
- [22] Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL receptor protein, LRP, is an apo-E binding protein. *Nature* 1989, 341: 162-164.
- [23] Goldstein JL, Brown MS. The LDL receptor. *Arterioscler Thromb Vasc Biol* 2009, 29: 431-438.
- [24] Abifadel M, Varret M, Rabes JP, Allard D, Ougeram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet* 2003, 34: 154-156.
- [25] Takahashi S, Sakai J, Fujino T, Zenimatu Y, Suzuki J, et al. The VLDL receptor: characterization and function as a peripheral lipoprotein receptor. *J Atheroscler Thromb* 2004, 11: 200-208.
- [26] Abhimanyu G, Vinaya S. Update on dyslipidemia. *J Clin Endocrinol Metab* 2007, 92: 1581-1589.
- [27] Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. *Science* 2001, 292: 1394-1398.
- [28] Soufi M, Ruppert V, Kurt B, Schaefer JR. The impact of severe LDL receptor mutations on SREBP-pathways regulation in homozygous familial hypercholesterolemia. *Gene* 2012, 499: 218-222.

- [29] Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apo-B mutation and familial defective apo-B100. *Proc Natl Acad Sci* 1989; 86: 587-591.
- [30] European Association for Cardiovascular Prevention & Rehabilitation. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 2011; 32: 1769-818.
- [31] Hovingh GK, Davidson MH, Kastelein JJP, O'Connor AM. Diagnosis and treatment of familial hypercholesterolemia. *European Heart J* 2013; 34: 962-971.
- [32] Johansen CT, Hegele RA. Genetic basis of hypertriglyceridemic phenotypes. *Curr Opin Lipidol* 2011; 22: 247-253.
- [33] Sniderman A, Tremblay A, Bergeron J, Gagnè C, Couture P. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride and apo-B. *J Clin Lipidol* 2007; 1: 256-263.
- [34] *Global atlas on cardiovascular disease prevention and control*, World Health Organization, 2011.
- [35] Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 2006; 3(11): e442.
- [36] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). *Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006*.
- [37] Dobiášová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER HDL). *Clinical Biochemistry* 2001; 34: 583-588.
- [38] Anitschkow N, Chalataw S. Ueber experimentelle Cholesterinsteatose und ihre Bedeutung fuer die Entstehung einiger pathologischer Prozesse. *Zentrbl Allg Pathol Pathol Anat* 1913; 24: 1-9.
- [39] Dawber TR, Meadors GF, More FE jr., Epidemiological approaches to heart disease: the Framingham Study. *Am J Public Health Nations Health* 1951; 41: 279-81.
- [40] The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease. *JAMA* 1976; 235: 825-7.
- [41] Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. *Lancet* 1986; 2(8506): 533-7.
- [42] Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. *Am J Cardiol* 1992; 70: 733-7.
- [43] Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. *Arterioscler Thromb* 1994; 14: 1098-104.
- [44] Rosamond W, Flegal K, Furie K, Go A, Greenlund K, et al. Heart Disease and Stroke Statistics 2008 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2008; 117: e25-e146.
- [45] The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. *JAMA* 1984; 251: 351-64.
- [46] Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005; 366(9493): 1267-78.
- [47] National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002; 106: 3143-421.
- [48] Palmieri L, Panico S, Vanuzzo D, Ferrario M, Pilotto L, Segà R, et al. La valutazione del rischio cardiovascolare globale assoluto: il punteggio individuale del progetto CUORE. *Ann Ist Super Sanità* 2004; 40: 393-9.
- [49] Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, Svetkey LP, Wadden TA, Yanovski SZ, Kendall KA, Morgan LC, Trisolini MG, Velasco G, Wnek J, Anderson JG, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Selke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014; 129 (25 Suppl 2): S76-99.
- [50] Metz JA, Kris-Etherton PM, Morris CD, Mustad VA, Stern JS, Oparil S, Chait A, Haynes RB, Resnick LM, Clark S, Hatton DC, McMahon M, Holcomb S, Snyder GW, Pi-Sunyer FX, McCarron DA. Dietary compliance and cardiovascular risk reduction with a prepared meal plan compared with a self-selected diet. *Am J Clin Nutr* 1997; 66: 373-85.
- [51] Hegsted DM. Serum-cholesterol response to dietary cholesterol: a re-evaluation. *Am J Clin Nutr* 1986; 44: 299-305.
- [52] [http://cholesterolbattle.com/wp-content/uploads/file/Serum\\_blood\\_cholesterol.pdf](http://cholesterolbattle.com/wp-content/uploads/file/Serum_blood_cholesterol.pdf)
- [53] Lapointe A, Couillard C, Lemieux S. Effects of dietary factors on oxidation of low-density lipoprotein particles. *J Nutr Biochem* 2006 Oct; 17(10): 645-58.
- [54] Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syv anne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, European Association for Cardiovascular Prevention & Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG). European

Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J* 2012; 33: 1635-701.

[55] Izzo R, de Simone G, Giudice R, Chinali M, Trimarco V, De Luca N, Trimarco B. Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia. *J Hypertens* 2010; 28: 1482-7.

[56] Svetkey LP, Simons-Morton D, Vollmer WM, Appel LJ, Conlin PR, Ryan DH, Ard J, Kennedy BM. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. *Arch Intern Med* 1999; 159: 285-93.

[57] de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation* 1999; 99: 779-85.